Vitamin D and Health

Hypertension
Table 42: Meta-analyses of RCTs and prospective studies of vitamin D supplementation/25(OH)D concentration on hypertension risk
Study Methods Results Conclusions
RCTs
Witham et al (2009)
Wu et al (2010)
Kunutsor et al (2014)
Beveridge et al (2015)
RCTs & Prospective studies
Pittas et al (2010)
Burgaz et al (2011)
Selection criteria:
Inclusion: RCTs comparing vitamin D with placebo (included studies
that used UVB light to produce an increase in 25(OH)D).
Exclusion: Not reported..
Selection criteria:
Inclusion: RCTs reporting baseline & follow up BP.
Exclusion: Uncontrolled trials, observational & animal studies;
studies in patients with kidney diseases, hypercalcemia, diabetes, or
impaired glucose tolerance; pregnant women & children..
Selection criteria:
Inclusion: RCTs on effects of vitamin D supplementation alone.
Exclusion: Studies with calcitriol or one of its analogues.
Selection criteria:
Inclusion: BP or other measures of vascular function as outcomes;
any baseline 25(OH)D concentration; BP reduction or changes in
surrogate markers of cardiovascular risk; minimum 4 weeks; vitamin
D2, D3, calcitriol, 1-α – hydroxylated version of vitamin D,
paricalcitol and doxerocalciferol.
Exclusion: Participants younger than 16 y or patients who were
receiving dialysis.
Selection criteria:
Inclusion: Studies in English language & in healthy populations. RCTs
of vit D supplementation ± calcium. Nested case control studies.
Exclusion: Cross-sectional, retrospective cohort & case control
studies and RCTs 140/90 mmHg) (8 studies; n=545)
Mean change in BP (intervention vs placebo)
SBP - 3.6 mmHg (95% CI, 8.0-0.7) p=0.1
DBP - 3.1mmHg (95% CI, -5.5 to -0.6) p=0.01
Studies with normal mean baseline BP (